These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria. Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989 [TBL] [Abstract][Full Text] [Related]
25. Using sound for microbial eradication--light at the end of the tunnel? Harris F; Dennison SR; Phoenix DA FEMS Microbiol Lett; 2014 Jul; 356(1):20-2. PubMed ID: 24861483 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821 [TBL] [Abstract][Full Text] [Related]
27. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Lynch AS Biochem Pharmacol; 2006 Mar; 71(7):949-56. PubMed ID: 16290174 [TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003. Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560 [TBL] [Abstract][Full Text] [Related]
29. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. Lister PD; Wolter DJ; Wickman PA; Reisbig MD J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915 [TBL] [Abstract][Full Text] [Related]
30. Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. Peppard WJ; Johnston CJ; Urmanski AM Expert Rev Anti Infect Ther; 2008 Feb; 6(1):83-99. PubMed ID: 18251666 [TBL] [Abstract][Full Text] [Related]
31. The antibiotic resistome: the nexus of chemical and genetic diversity. Wright GD Nat Rev Microbiol; 2007 Mar; 5(3):175-86. PubMed ID: 17277795 [TBL] [Abstract][Full Text] [Related]
33. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. Lister PD Biochem Pharmacol; 2006 Mar; 71(7):1057-65. PubMed ID: 16316633 [TBL] [Abstract][Full Text] [Related]
38. Treatment options for multidrug-resistant bacteria. Giamarellou H Expert Rev Anti Infect Ther; 2006 Aug; 4(4):601-18. PubMed ID: 17009940 [TBL] [Abstract][Full Text] [Related]
39. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
40. What is in the pipeline for Gram-negative pathogens? Talbot GH Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]